Ipamorelin

Product Overview

 Ipamorelin Peptide is a synthetic pentapeptide and a growth hormone secretagogue (GHS) that selectively activates the ghrelin receptor (GHS-R1a) to stimulate growth hormone release from the anterior pituitary. Developed by Novo Nordisk in the late 1990s under the research designation NNC 26-0161, it was the first GHS to demonstrate highly selective GH stimulation without significant elevation of cortisol, ACTH, or prolactin.

As a ghrelin mimetic, Ipamorelin is distinct from earlier GHRPs due to its precise receptor targeting. It is believed to provoke robust GH release comparable to GHRP-6 yet without the collateral stimulation of stress-related hormones. This selectivity makes it a valuable investigative tool for researchers aiming to isolate GH pathways in controlled laboratory settings.

⚠️ Research Context: This product is intended exclusively for in-vitro and laboratory research purposes. It is not FDA-approved for human use and is listed on the WADA Prohibited List (S2.2.4) as a growth hormone secretagogue.

 Ipamorelin Peptide Mechanism of Action

Ipamorelin functions through selective activation of the ghrelin receptor (GHS-R1a):

• GHS-R1a Agonism: Binds to ghrelin receptors primarily in GHRH-positive neurons in the hypothalamus and on somatotroph cells in the anterior pituitary.

• Pulsatile GH Release: Triggers the release of growth hormone in a pulsatile pattern that preserves hypothalamic feedback mechanisms.

• Hormonal Selectivity: Ipamorelin was specifically designed to avoid interactions with receptors involved in cortisol, ACTH, or prolactin pathways. Research demonstrates that equimolar doses stimulate GH at levels comparable to GHRP-6 while producing no statistically significant elevation in ACTH or cortisol.

Receptor Activation Effects:

• Growth Hormone Release: Stimulates GH secretion through GHS-R1a activation.

• Gastric Motility: GHS-R1a receptors are also present in the gastrointestinal tract; ipamorelin has been shown to stimulate gastric acid secretion and gastric motility in research models.

• Appetite Regulation: As a ghrelin mimetic, ipamorelin influences food intake and body weight dynamics in animal studies.

Key Research Applications:

• GHS-R receptor pharmacology and signaling studies

• GH axis and pulsatile secretion research

• Endocrine selectivity investigations

• Gastrointestinal motility research

Product Specifications

Quality Control Specifications

Certificate of Analysis (COA) available upon request.

Research Background

Discovery and Development

Ipamorelin Peptide emerged from a medicinal chemistry program at Novo Nordisk aimed at identifying highly selective growth hormone secretagogues. A 1998 paper published in the European Journal of Endocrinology first described ipamorelin as “the first selective growth hormone secretagogue” — a pentapeptide that released GH in conscious swine with potency comparable to GHRP-6 but without the ACTH, cortisol, or prolactin elevations seen with earlier GHRPs. The structure-activity relationship (SAR) program was detailed in a companion paper in the Journal of Medicinal Chemistry that same year. Ipamorelin Peptide

Selectivity Profile

 Ipamorelin Peptide’s three-way selectivity — GH stimulation without cortisol, prolactin, or ACTH elevation — established it as the benchmark for GHS selectivity in the academic literature. Ipamorelin Peptide

Preclinical Research Findings

Clinical and Regulatory Status

• FDA Status: Not approved for human use. As of September 2023, classified as a Category 2 bulk drug substance under Section 503A of the FD&C Act, prohibiting use in compounded medications for human administration.

• WADA Status: Prohibited both in and out of competition (S2.2.4 – Growth hormone secretagogues).

• Clinical Research: One Phase 2 randomized controlled trial for postoperative ileus (2014) failed to meet its primary endpoint.

• Regulatory: Not listed on the Australian Register of Therapeutic Goods (ARTG).

Storage & Reconstitution Guidelines

Storage Conditions:

• Lyophilized (Long-term): -20°C, protected from light, dry, sealed

• Lyophilized (Short-term): 2°C – 8°C (refrigerated)

• Reconstituted: 4°C for up to 7 days; aliquot for extended storage; avoid repeated freeze-thaw cycles

Reconstitution Protocol:

1. Allow vial to reach room temperature

2. Add sterile bacteriostatic water or 0.9% sodium chloride solution

3. Gently swirl (do not vortex) until fully dissolved

4. Dispense into individual aliquots to minimize freeze-thaw degradation

Note: Peptides are sensitive to formulation, process, and environmental conditions that may lead to aggregation and degradation.

Important Notice

⚠️ FOR RESEARCH USE ONLY

This product is not intended for human consumption, diagnostic use, therapeutic application, or clinical administration. Ipamorelin Peptide is a research chemical intended exclusively for in-vitro and laboratory research purposes.

• Not approved by the FDA for human use

• Not a dietary supplement, food additive, or pharmaceutical for over-the-counter purchase

• Prohibited by the World Anti-Doping Agency (WADA S2.2.4)

• Intended solely for qualified researchers and scientific institutions

By purchasing this product, you confirm that you are a licensed researcher or laboratory professional and agree to use this compound in compliance with all applicable local, national, and international regulations.

Why Choose PeptidesUnit.com?

Order Now

Ipamorelin Peptide 5mg – ≥99% Purity
Available for immediate shipment. Ipamorelin Peptide

🛒 BUY NOW at PeptidesUnit.com